摘要
目的探讨肥大细胞活化产物的促进血管生成作用。方法分离SD大鼠腹腔肥大细胞(RPMC),用钙离子载体刺激使其活化,提取活化产物并检测其类糜蛋白酶活性。选取BALB/c小鼠30只,随机分为对照组、活化产物组和抑制剂组(每组10只),用基质胶栓模型来研究活化产物的血管生成作用。采用氰化高铁血红蛋白(HiCN)法测定胶体内血红蛋白(Hb)浓度,HE染色观察胶体内血管分布情况,并用CD34免疫组织化学染色法检测基质胶中血管密度(MVD)。结果分离获得的RPMC激活后可以检测到类糜蛋白酶活性。小鼠基质胶栓实验显示,活化产物注射组基质胶内的Hb水平约为对照组的7倍,而抑制剂组的Hb水平比实验组下降了80.8%。HE染色显示,实验组基质胶中可见新生血管,有些可以观察到血管腔。MVD检测结果显示活化产物组的MVD约为对照组的5倍,而抑制剂组比实验组下降66.2%。结论肥大细胞活化产物中类糜蛋白酶是促进小鼠基质胶栓中血管生成的主要介质。
Objective To investigate the role of mast cell activation products in promoting angiogenesis.Methods SD rat peritoneal mast cells(RPMC)were isolated and activated by calcium ionophore.The activation products were extracted and the activity of chymase was detected.Thirty BALB/c mice were randomly divided into a control group,an activation product group,and an inhibitor group(10 mice in each group),and the angiogenisis of mast cell activation products was studied by matrigel plug assay.In the matrigel plug,the hemoglobin(Hb)concentration was determined by hemiglobincyanide(HiCN)method,the distribution of blood vessels was observed by HE staining,and the microvessel density(MVD)was detected by CD34 immunohistochemical staining.Results The activity of chymase was detected in the activation products of isolated RPMCs.The results of mice matrigel plug assay showed that the Hb level in matrigel plug of the activation product group was about 7 times higher than that of the control group,while the Hb level of the inhibitor group was 80.8%lower than that of the activation product group.HE staining showed new blood vessels in the matrigel plug of the activation product group,and some vascular lumens were observed.The results of MVD showed that the MVD in matrigel plug of the activation product group was about 5 times than that of the control group,while MVD of the inhibitor group was 66.2%lower than that of the activation product group.Conclusion Chymase,a product of mast cell activation,is the main mediator to promote angiogenesis in mouse matrigel plugs.
作者
侯玉涛
梁晓东
车辑
梁朋朋
陈章权
HOU Yutao;LIANG Xiaodong;CHE Ji;LIANG Pengpeng;CHEN Zhangquan(Department of Blood Transfusion,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029;Department of Clinical Immunology,Guangdong Medical University,Dongguan 523808;Department of Laboratory,Jiangmen Central Hospital,Jiangmen 529030;Department of Pediatrics,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China)
出处
《细胞与分子免疫学杂志》
CAS
CSCD
北大核心
2021年第12期1073-1078,共6页
Chinese Journal of Cellular and Molecular Immunology
基金
广东省自然科学基金(9152402301000018)
广东省大学生创新实验项目(KY1039)。
